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DISCLOSURE SUPPLEMENT AND ILLUSTRATIVE FINANCIAL STATEMENTS FOR
DEVELOPMENT STAGE ENTERPRISES
The checklists and illustrative financial statements 
included in this booklet have been developed by the 
staff of the Technical Information Division of the 
AICPA as a nonauthoritative technical practice aid. 
Readers should be aware of the following:
o The checklists and illustrative financial state­
ments are to be used in conjunction with the 
"Disclosure Checklists and Illustrative Financial 
Statements for Corporations," and have been up­
dated to include relevant FASB Statements and 
AICPA Statements of Position. The checklist and 
illustrative financial statements should be modi­
fied, as appropriate, for subsequent pronounce­
ments. In determining the applicability of a 
pronouncement, its effective date should also be 
considered.
o The checklists and illustrative financial state­
ments should be used by or under the supervision 
of persons having adequate technical training and 
proficiency in the application of generally 
accepted accounting principles, generally accepted 
auditing standards, and statements on standards 
for accounting and review services.
o The checklists and illustrative financial state­
ments do not represent minimum requirements and do 
not purport to be all-inclusive. The referenced 
standard should be reviewed if clarification is 
desired as to whether the disclosures indicated 
are required or suggested, and to what extent the 
disclosure is relevant to the statements being 
examined.
Users of these checklists and illustrative financial 
statements are urged to refer directly to applicable 
authoritative pronouncements. If you have further 
questions, call the AICPA Technical Hotline 
(see back cover).
John Graves
Director
Technical Information Division
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INTRODUCTION
The unprecedented growth in the U.S. economy has resulted in an in­
crease in the number of companies in a development stage, as well as 
established operating companies1 starting new businesses.
A development stage enterprise is a company which devotes substan­
tially all of its effort to establishing a new business and in which 
either planned principal operations have not commenced, or planned 
principal operations have commenced, but there has been no significant 
revenue.
SPAS No. 7, Accounting and Reporting by Development Stage Enterprises, 
explains that devoting substantially all efforts to establishing a new 
business typically includes:
o financial planning 
o raising capital
o exploring for or developing natural resources 
o research and development 
o establishing sources of supply
o acquiring property, plant, equipment, or other operating 
assets
o recruiting and training personnel 
o developing markets 
o starting up production
Once the conditions in the second preceding paragraph are no longer 
met, the enterprise ceases to be in the development stage.
The generally accepted accounting principles that apply to the fi­
nancial statements of established operating companies also apply 
to the financial statements of development stage enterprises.
1The following are excluded from consideration as a development 
stage enterprise:
a. The expansion of an established operating company into a new 
line of business,
b. The conduct of exploration and development activities by 
established operating companies in the extractive industries, 
and
c. The development of properties by established operating com­
panies in the real estate industry.
(Note: SFAS No. 7 applies to separate financial statements of a
development stage subsidiary or other investee of established 
operating companies.)
1
SFAS No. 7 permits development stage enterprises to defer only 
those costs that established operating companies would be per­
mitted to defer under GAAP. Likewise, development stage enterpri­
ses should charge to expense those costs that established 
operating companies would charge to expense. Statement of 
Financial Accounting Concepts No. 5, Recognition and Measurement 
in Financial Statements of Business Enterprises, states that 
expenses are generally recognized when an entity's economic bene­
fits are used up in delivering or producing goods, rendering ser­
vices, or other activities that constitute its ongoing major or 
central operations.
Typically, significant research and development costs are incurred 
by development stage enterprises. SFAS No. 2, Accounting for 
Research and Development Costs, requires all entities (including 
development stage enterprises) to expense research and development 
costs as incurred.
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Disclosure Supplement and Illustrative Financial
Statements for Development Stage Enterprises
This checklist has been developed by the staff of the Technical 
Information Division of the AICPA as a nonauthoritative practice aid, 
and is to be used in conjunction with the Disclosure Checklists and 
Illustrative Financial Statements for Corporations.
Explanation of references:
APB = Accounting Principles Board Opinion 
SFAS = Statement of Financial Accounting Standards 
(AC) = Reference to section number in FASB Accounting Standards
Current Text
SOP = AICPA Statement of Position
Checklist Questionnaire
Financial Statements and Notes Checklist for
Development Stage Enterprises
Note: This checklist is to be used in conjunction with Financial
Statement Preparation Manual Section 2500, "Disclosure 
Checklists for Corporations."
General Yes No N/A
Financial Statement Titles and Disclosure
1. Are the financial statements identified
as those of a development stage enterprise 
(in the notes to the financial statements or
parenthetically in each statement heading)? ___
[SFAS No. 7, paragraph 12]
2. Do the financial statements include a
description of the nature of the develop­
ment stage activities in which the enter­
prise is engaged? ___
[SFAS No. 7, paragraph 12]
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Balance Sheet
General
o Does the balance sheet presentation include 
the report of any cumulative2 net losses with 
a descriptive caption such as "Deficit Accu­
mulated During the Development Stage" in the
stockholders' equity section? ___ ___ ___
[SFAS No. 7, paragraph 11 a.]
Statement of Operations
General
1. Does the income statement report amounts of 
revenue and expenses for each period covered 
and, in addition, cumulative3 amounts from
the enterprise's inception? ___ ___ ___
[SFAS No. 7, paragraph 11 b.]
2. If a formerly dormant enterprise was re­
activated to undertake development stage 
activities, has disclosure of cumulative 
amounts of revenue and expenses been re­
ported from inception of the development
stage? ___ ___ ___
[SFAS 7, paragraph 11, footnote 7]
Statement of Stockholders' Equity
o Does the statement of stockholders' equity 
report from the enterprise's inception4:
a. The date and number of shares of stock, 
warrants, rights, or other equity secu­
rities issued for cash and for other 
consideration for each issuance?
Yes No N/A
2Note that cumulative information from development stage enterprises' 
inception is part of the basic required information for the financial 
statements to be presented in accordance with GAAP. Generally, such 
information is presented in a column adjacent to the financial state­
ments for the period(s) of the engagement.
3Ibid.
4Ibid.
4
Yes No N/A
b. The dollar amounts (per share or other 
equity unit and in total) assigned to 
the consideration received for shares 
of stock, warrants, rights, or other 
equity securities for each issuance?
[Were dollar amounts assigned to any 
noncash consideration received?]
c. The nature of the noncash consideration 
and the basis for assigning amounts for 
each issuance involving noncash consid­
eration?
[SFAS No. 7, paragraph 11 d.]
Statement of Cash Flows
General
o Does the cash flows statement report cash 
flows from operating, investing, and fi­
nancing activities for each period for 
which an income statement is presented and, 
in addition, cumulative5 amounts from the 
enterprise’s inception?
[SFAS No. 7, paragraph 11 c, as amended by 
SFAS No. 95]
5Ibid.
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ILLUSTRATIVE INDEPENDENT AUDITOR’S REPORT 
(Unqualified Opinion)
Independent Auditor’s Report
We have audited the accompanying balance sheets of DSE, Inc. (a development stage enterprise) as of December 
3 1 ,  19X7 and 19X6, and the related statements of operations, shareholders' equity (deficiency) and cash flows for 
the years then ended and for the period from July 1 ,  19X1 (inception) to December 3 1 , 19X7. These financial state­
ments are the responsibility of the Company's management. Our responsibility is to express an opinion on these 
financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing standards. Those standards require that 
we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of 
material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and dis­
closures in the financial statements. An audit also includes assessing the accounting principles used and signifi­
cant estimates made by management, as well as evaluating the overall financial statement presentation. We believe 
that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial posi­
tion of DSE, Inc. (a development stage enterprise) as of December 3 1 , 19X7 and 19X6, and the results of its opera­
tions and its cash flows for the years then ended and for the period from July 1 ,  19X1 (inception) to December 31, 
19X7 in conformity with generally accepted accounting principles.
[Signature]
[Date]
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ILLUSTRATIVE BALANCE SHEETS 
DSE, Inc.
(A Development Stage Enterprise) 
Balance Sheets 
December 3 1 , 19X7 and 19X6
December 31
19X7 19X6
Assets
Current assets 
Cash and cash equivalents 
Certificates of deposit
Investments in United States Treasury Securities
Accrued interest receivable
Prepaid expenses and other current assets
Total Current Assets
Property, Plant and Equipment 
Furniture and fixtures 
Equipment
Leasehold improvements
Accumulated depreciation and amortization
$ XXX,XXX 
XXX,XXX 
X,XXX,XXX 
XX,XXX 
XX,XXX 
x,xxx,xxx
$ XXX,XXX 
XXX,XXX 
X,XXX,XXX 
XXX,XXX 
XXX,XXX
X,XXX,XXX
Other Assets
Investments in United States Treasury Notes 
Patent rights, net of accumulated amortization
of $XX,XXX in 19X7 and $XX,XXX in 19X6
XXX,XXX 
X,XXX,XXX
XXX,XXX 
X,XXX,XXX 
(X,XXX,XXX)
XXX,XXX
X,XXX,XXX
XX,XXX 
X,XXX,XXX 
$ X,XXX,XXX
XXX,XXX 
XXX,XXX 
XXX,XXX 
XXX,XXX 
(XXX,XXX) 
XXX,XXX 
XXX,XXX
XX,XXX 
XXX,XXX
$ X,XXX,XXX
Liabilities and Shareholders' Equity
Current Liabilities 
Accounts payable 
Accrued expenses 
Accrued salaries
Total Current Liabilities
Deferred Compensation
Shareholders' Equity 
Common Stock
Class A, $.XX par value—authorized XX,XXX,XXX 
shares; issued and outstanding X,XXX,XXX 
shares in 19X7 and X,XXX,XXX shares in 19X6
Class B, $.XX par value—authorized X,XXX,XXX 
shares; issued and outstanding X,XXX,XXX 
shares in 19X7 and X,XXX,XXX shares in 19X6
Additional paid-in capital
Deficit accumulated during the development stage
$ XXX,XXX 
XX,XXX 
XX,XXX
XXX,XXX 
XXX,XXX
$ XXX,XXX 
XX,XXX 
XX,XXX
XXX,XXX 
XXX,XXX
XXX,XXX XXX,XXX
XXX, XXX 
XX,XXX,XXX 
(X,XXX,XXX) 
X,XXX,XXX 
$ X,XXX,XXX
XXX,XXX 
XX,XXX,XXX 
(X,XXX,XXX) 
X,XXX,XXX 
$ X,XXX,XXX
The accompanying notes are an integral part of these financial statements.
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ILLUSTRATIVE STATEMENTS OF OPERATIONS 
DSE, Inc.
(A Development Stage Enterprise) 
Statements of Operations 
Years Ended December 3 1 , 19X7 and 19X6, and 
the Period from July 1 ,  19X1 (Date of Inception) 
to December 3 1 , 19X7
Period
From
July 1 ,  19X1 
(Inception)
Year Ended December 31 Through
December 3 1 ,  19X719X7 19X6
Interest Income $ XXX,XXX $ XXX,XXX $ X,XXX,XXX
Expenses
Salaries, benefits, and payroll taxes X,XXX,XXX X,XXX,XXX X,XXX,XXX
Research fees and clinical trials XXX,XXX XXX,XXX X,XXX,XXX
Research supplies XXX,XXX XXX,XXX X,XXX,XXX
Depreciation and amortization XXX,XXX XXX,XXX X,XXX,XXX
Legal and professional XXX,XXX XXX,XXX X,XXX,XXX
Rent XXX,XXX XXX,XXX XXX,XXX
Shareholder and public relations XXX,XXX XXX,XXX XXX,XXX
Scientific advisory and consulting XXX,XXX XX,XXX XXX,XXX
Equipment leasing XXX,XXX XXX,XXX XXX,XXX
Repairs and maintenance XX,XXX XX,XXX XXX,XXX
Travel and entertainment XX,XXX XX,XXX XXX,XXX
Taxes and licenses XX,XXX XX,XXX XXX,XXX
Insurance XX,XXX XX,XXX XXX,XXX
Recruiting and relocation XX,XXX XX,XXX XXX,XXX
Telephone XX,XXX XX,XXX XX,XXX
Directors' fees XX,XXX XX,XXX XX,XXX
Office supplies XX,XXX XX,XXX XX,XXX
General and administrative XX,XXX XX,XXX XX,XXX
Utilities XX,XXX XX,XXX XX,XXX
Postage and courier XX,XXX XX,XXX XX,XXX
Net Loss
X,XXX,XXX 
$(X,XXX,XXX)
X,XXX,XXX 
$(X,XXX,XXX)
XX,XXX,XXX 
$ (X,XXX,XXX)
Loss per Common Share $(.XX) $(.XX) $(.XX)
The accompanying notes are an integral part of these financial statements.
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ILLUSTRATIVE STATEMENTS OF SHAREHOLDERS’ EQUITY 
DSE, Inc.
(A Development Stage Enterprise)
Statements of Shareholders’ Equity 
Years Ended December 3 1 , 19X7 and 19X6, and the 
Period from July 1 ,  19X1 (Date of Inception) 
to December 3 1 , 19X7
Additional
Common Stock_____  Paid-In
Class A Class B Capital
Deficit
Accumulated 
During the 
Development 
Stage
Balances at July 1 ,  19X1 (Inception)
July 5 ,  19X1—Sale of XXX,XXX shares of Class A 
Common Stock—$.XXXX per share
July 5 ,  19X1—Issuance of X,XXX,XXX shares of Class B 
Common Stock for patent rights
August 1 7 , 19X1—Sale of XXX,XXX shares of Class A 
Common Stock—$.XXXX per share
October 1 5 , 19X1—Private placement of X,XXX,XXX 
shares of Class A Common Stock—$.XXXX per share
October 1 5 , 19X1—Issuance of XXX,XXX shares of Class 
A Common Stock for financial services
Costs relating to the sale of Class A Common Stock 
Net loss for the period
Balances at December 3 1 , 19X1
Net loss for the year
Balances at December 3 1 , 19X2
May 1 0 , 19X3—Exchange of XX, XXX shares of Class B 
Common Stock for XX,XXX shares of Class A 
Common Stock
September 1 ,  19X3—Sale of XX,XXX shares of Class A 
Common Stock to outside director under Stock 
Option Agreement—$.XXXX per share
Net loss for the year
Balances at December 3 1 , 19X3
January 1 7 , 19X4—Sale of X,XXX,XXX shares of Class A 
Common Stock in Initial Public Offering—$X.XX 
per share
January 26, 19X4—Sale to underwriter of warrants to 
purchase XXX,XXX shares of Class A Common Stock
February 2 9 , 19X4—Sale of X,XXX shares of Class A 
Common Stock to outside director under Stock 
Option Agreement—$.XXXX per share
Costs relating to sale of Class A Common Stock in 
Initial Public Offering
September 3 0 , 19X4—Sale of XX,XXX shares of Class A 
Common Stock to outside director under Stock 
Option Agreement—$.XXXX per share
December 7 ,  19X4—Change in par value of Class A and 
Class B Common Stock from no par value to $.XX 
par value
Net loss for the year
Balances at December 3 1 , 19X4
$ XXX,XXX
$ X
XXX,XXX
X,XXX,XXX
XXX,XXX 
(XX,XXX)
X,XXX,XXX X —
X,XXX,XXX X —
XX,XXX X
XX,XXX
X,XXX,XXX X —
$ (XX,XXX) 
(XX,XXX)
(XXX,XXX) 
(XXX,XXX)
(XXX,XXX) 
(X,XXX,XXX)
$xx,xxx,xxx
$ XXX
x,xxx
(XXX,XXX)
XX,XXX
(XX,XXX,XXX) XXX,XXX XX,XXX,XXX
XXX,XXX XXX,XXX XX,XXX,XXX
$ (XXX,XXX) 
(X,XXX,XXX)
The accompanying notes are an integral part of these financial statements.
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ILLUSTRATIVE STATEMENTS OF SHAREHOLDERS’ EQUITY—CONTINUED 
DSE, Inc.
(A Development Stage Enterprise)
Statements of Shareholders’ Equity 
Years Ended December 3 1 , 19X7 and 19X6, and the 
Period from July 1 ,  19X1 (Date of Inception) 
to December 3 1 , 19X7
July 24, 19X5—Exchange of XXX,XXX shares of Class B 
Common Stock for XXX,XXX shares of Class A 
Common Stock
Net loss for the year
Balances at December 3 1 , 19X5
May 20, 19X6—Sale of XX shares of Class A Common 
Stock to employee under Incentive Stock Option 
Agreement—$.XXXX per share
July 1 through December 3 1 , 19X6 (various dates)—
Sale of X,XXX shares of Class A Common Stock to 
employee under Incentive Stock Option Agreement 
—$X.XXX per share
Net loss for the year
Balances at December 3 1 , 19X6
January 15 through November 13, 19X7 (various dates) 
—Sale of X,XXX shares of Class A Common Stock to 
employee under Incentive Stock Option Agreement 
—$X.XXX per share
February 27 through April 23, 19X7 (various dates)— 
Sale of XXX,XXX shares of Class A Common Stock to 
underwriter under terms of warrants—$X.XX per share
Costs relating to sale of Class A Common Stock to 
underwriters
March 3 1 , 19X7-Exchange of XXX,XXX shares of Class 
B Common Stock for XXX,XXX shares of Class A 
Common Stock
December 21, 19X7—Grant of X,XXX shares of Class A 
Common Stock to employees as bonuses for 19X7 
services
Net loss for the year
Balances at December 3 1 , 19X7
Deficit
Accumulated
Common Stock
Additional
Paid-In
Capital
During the 
Development 
StageClass A Class B
x,xxx (X,XXX)
(X,XXX,XXX)
XXX,XXX XXX,XXX XX,XXX,XXX (X,XXX,XXX)
X XX
XX x,xxx
(X,XXX,XXX)
XXX,XXX XXX,XXX XX,XXX,XXX (X,XXX,XXX)
XX x,xxx
XX,XXX X,XXX,XXX
(XX,XXX)
XX,XXX (XX,XXX)
XXX XX,XXX
(X,XXX,XXX)
$xxx,xxx $xxx,xxx $xx,xxx,xxx $(X,XXX,XXX)
The accompanying notes are an integral part of these financial statements.
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ILLUSTRATIVE STATEMENTS OF CASH FLOWS 
(Direct Method)
DSE, Inc.
(A Development Stage Enterprise) 
Statements of Cash Flows 
Years Ended December 3 1 , 19X7 and 19X6, and the 
Period from July 1 ,  19X1 (Date of Inception) 
to December 3 1 , 19X7
Cash flows from operating activities:
Cash paid to suppliers and employees 
Interest received
Other cash payments
Net Cash Used in Operating Activities
Cash flows from investing activities:
Proceeds from sale and maturities of investments 
Acquisition of investments
Acquisition of property, plant and equipment 
Patent rights and organization costs
Net Cash Provided by (Used in) Investing Activities
Cash flows from financing activities:
Proceeds from common stock issues 
Costs of the sales of common stock
Net Cash Provided by Financing Activities
Net Increase (Decrease) in Cash and Cash Equivalents 
Cash and Cash Equivalents at Beginning of Year
Cash and Cash Equivalents at End of Year
Period
From
July 1, 19X1 
(Inception)
Year Ended December 31 Through
19X7 19X6 December 31, 19X7
$(X,XXX,XXX) $(X,XXX,XXX) $ (X,XXX,XXX)
XXX,XXX XXX,XXX XXX,XXX
(XXX,XXX) (XXX,XXX) (XXX,XXX)
(X,XXX,XXX) (X,XXX,XXX) (X,XXX,XXX)
X,XXX,XXX X,XXX,XXX XX,XXX,XXX
(X,XXX,XXX) (XXX,XXX) (XX,XXX,XXX)
(XXX,XXX) (XXX,XXX) (X,XXX,XXX) 
(XX,XXX)
X,XXX,XXX X,XXX,XXX (X,XXX,XXX)
X,XXX,XXX x,xxx XX,XXX,XXX
(XX,XXX) (XXX,XXX)
X,XXX,XXX x,xxx XX,XXX,XXX
XXX,XXX XX,XXX XXX,XXX
XXX,XXX XX,XXX —
$ XXX,XXX $ XXX,XXX $ XXX,XXX
The accompanying notes are an integral part of these financial statements.
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ILLUSTRATIVE STATEMENTS OF CASH FLOWS—CONTINUED 
(Direct Method)
DSE, Inc.
(A Development Stage Enterprise)
Statements of Cash Flows 
Reconciliation of Net Loss to Net Cash 
Used in Operating Activities 
Years Ended December 3 1 , 19X7 and 19X6, and the 
Period from July 1 ,  19X1 (Date of Inception) 
to December 3 1 , 19X7
Net loss
Adjustments to reconcile net loss to net cash 
provided by operating activities:
Grant of employee stock bonuses 
Depreciation and amortization 
Gain on disposal of fixed assets 
Investment discount and premium
amortization
(Increase) decrease in interest earned but not 
received
(Increase) decrease in prepaid expenses and other 
current assets
Increase (decrease) in accounts payable, accrued 
expenses, and accrued salaries
Deferred compensation 
Total adjustments
Net Cash Used in Operating Activities
Period
From
July 1 ,  19X1 
(Inception)
Year Ended December 31 Through
19X7 19X6 December 3 1 ,  19X7
$(X,XXX,XXX) $(X,XXX,XXX) $(X,XXX,XXX)
XX,XXX 
XXX,XXX XXX,XXX 
(XX)
XX,XXX
X,XXX,XXX 
(XX)
XXX (X,XXX) (XX,XXX)
XX,XXX XXX,XXX (XX,XXX)
XXX,XXX (XXX,XXX) (XX,XXX)
(XXX,XXX) 
XX,XXX
XXX,XXX 
XX,XXX
XXX,XXX 
XXX,XXX
XXX,XXX XXX,XXX X,XXX,XXX
(X,XXX,XXX) (X,XXX,XXX) (X,XXX,XXX)
The accompanying notes are an integral part of these financial statements.
[Editor's note—SFAS No. 95, Statement of Cash Flows, requires disclosure of information about all investing and 
financing activities of an enterprise (including a development stage enterprise) during a period that affect recognized 
assets or liabilities but do not result in cash receipts or cash payments in the period. There were not any noncash 
investing and financing activities in this illustration.]
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ILLUSTRATIVE NOTES TO FINANCIAL STATEMENTS 
DSE, Inc.
(A Development Stage Enterprise)
Notes to Financial Statements
Note A—Organization and Significant Accounting Policies
DSE Inc., (the Company) is a development stage enterprise which engages in the research and development of 
several technological findings in the field of immunology and cancer detection. The Company's activities are 
directed toward the development of these discoveries for commercial and technical use.
Property, plant and equipment is stated on the basis of cost. Furniture and equipment is depreciated using the 
straight-line method over five years. Leasehold improvements are amortized over the life of the lease.
Certain legal fees and other expenses have been capitalized as patent rights and are being amortized using the 
straight-line method over 17 years. The Company has capitalized only legal fees and other expenses related to pat­
ent rights acquired; all other such costs have been expensed as incurred.
For purposes of the statements of cash flows, the Company considers all highly liquid investments with a maturity 
of three months or less to be cash equivalents. Certificates of deposit and United States Treasury Securities are 
combined as investments in the statements of cash flows.
Note B—Investments
Investments consisted of the following at the dates indicated:
Face
Value
Book
Value
Market
Value
December 3 1 ,  19X7
United States Treasury Bills
United States Treasury Notes
$ XXX,XXX
X,XXX,XXX
$ XXX,XXX
X,XXX,XXX
$ XXX,XXX 
X,XXX,XXX
$X,XXX,XXX $X,XXX,XXX $X,XXX,XXX
December 3 1 ,  19X6
United States Treasury Bills
United States Treasury Notes
$X,XXX,XXX
X,XXX,XXX
$X,XXX,XXX
X,XXX,XXX
$X,XXX,XXX 
X,XXX,XXX
$X,XXX,XXX $X,XXX,XXX $X,XXX,XXX
Note C—Deferred Compensation
The President of the Company has an employment contract with the Company that extends through December 31, 
19X8. The terms of this employment contract provide for extensions through 20X5.
Effective September 1,19X7, the base compensation under the contract was increased from $XX,XXX to $XXX,XXX 
per year. The contract provides for additional compensation of X% of income before income taxes (if any), not to 
exceed $XX,XXX. In addition, the contract provides for deferred compensation of $XX,XXX per year payable upon 
the President's termination of employment in monthly installments over 10 years or in one lump sum, at the option 
of the Company. The yearly credits to deferred compensation are adjusted by increases in the Consumer Price 
Index for All Urban Consumers. If the Company elects to pay the deferred compensation in installments, interest 
on the unpaid balance will be added to each installment payment computed at the prime rate in effect at the install­
ment date. The President was 100% vested in the deferred compensation balance under the contract as of December 
3 1 ,  19X7 and 19X6. Deferred compensation expense under the contract included in salaries, benefits, and payroll 
taxes was $XX,XXX and $XX,XXX for the years ended December 31, 19X7 and 19X6, respectively.
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Effective March 1 ,  19X5, the Company entered into an employment contract with Dr. Alpha, Secretary of the Com­
pany and wife of Dr. Beta, President of the Company, to assume the duties of Vice President for Medical Affairs 
for the Company. This employment contract expires on March 3 1 , 19Y0 and contains automatic renewal provisions 
for extensions through 20X5. The cancellation provision of this contract requires that a two-year written notice be 
given beginning after March 31, 19X8 if the Company elects to avoid automatic annual renewals.
The original contract specifies a base compensation of $XXX,XXX per year, reduced by the amount of salary drawn 
in any month for services performed by Dr. Alpha for a local university or drawn in any month for services per­
formed by Dr. Alpha for a local university. Effective September 1 ,  19X7, the contract was amended such that the 
base compensation paid to Dr. Alpha is no longer reduced by the amount of salary drawn in any month for services 
performed by Dr. Alpha for a local university. The contract also provides that XX% of annual compensation be 
credited to a deferred compensation account. The deferred compensation is payable at termination in monthly 
installments over a period not exceeding five years or in one lump sum, at the option of the Company. The deferred 
amount is adjusted semi-annually for the incremental interest which would have been earned at the United States 
Treasury Bill rate in effect the day following the credit date. If the Company elects to pay the deferred compensation in 
installments, interest on the unpaid balance will be added to each installment payment computed at the prime rate 
in effect at the installment date. Dr. Alpha was 100% vested in the deferred compensation balance under the con­
tract as of December 3 1 ,  19X7 and 19X6. Deferred compensation expense under the contract included in salaries, 
benefits, and payroll taxes was $XX,XXX and $X,XXX for the years ended December 3 1 , 19X7 and 19X6, respectively.
During 19X2, 19X3, and 19X5 through 19X7, the Company adopted deferred compensation agreements for certain 
key employees with benefits commencing at termination. Under the agreements, XX% of the employees' yearly 
compensation is deferred. The deferred amount is adjusted semi-annually for the incremental interest which 
would have been earned at the United States Treasury Bill rate in effect the day following the credit date. The 
deferred compensation vests in various proportions over a five-year period. Deferred compensation expense 
under these agreements totaled $XX,XXX and $X,XXX for the years ended December 3 1 ,  19X7 and 19X6, respec­
tively. In April 19X6 and March 19X5, employees resigned for whom compensation had been deferred under such 
agreements. The employees were only partially vested in the deferred compensation and, accordingly, $X,XXX in 
19X6 and $X,XXX in 19X5 (the nonvested amounts) were credited against expense.
Officers and employers were fully vested in $XXX,XXX of the $XXX,XXX deferred compensation liability at 
December 31, 19X7.
Note D—Income Taxes
The Company has no taxable income to date; therefore, no provisions for federal or state income taxes have been 
made. The deficit accumulated during the development stage is generally available to offset future taxable income. 
Investment tax credits (ITC) of approximately $XX,XXX and research expenditure tax credits of approximately 
$XXX,XXX are also available as of December 3 1 ,  19X7 to offset federal income taxes, if any, in future periods. The 
amount of ITC available at December 3 1 , 19X7 is scheduled to be reduced by 35% in 19X8 and thereafter under the 
provisions of the Tax Reform Act of 1986. These carryovers and credits expire in 19Y6 through 20X2.
Note E—Commitments
The Company has an agreement with a local university, with which the President and the Secretary and Vice- 
President for Medical Affairs of the Company are affiliated, to fund a chair in immunology. The Company is 
required to make annual payments of X% of net income (if any) into an endowment fund. The Company will be 
released from the agreement when the endowment fund reaches $XXX,XXX. The university may release the Com­
pany from the agreement to fund such chair at any time.
The Company has operating leases for its offices and research facilities in New York and Washington, D.C., which 
expire in 19Y1 and 19X9, respectively. The Company also has operating leases for various items of equipment 
which expire in 19X9 and 19Y0.
Future minimum annual lease payments as of December 31, 19X7 consist of the following:
19X8 $ XXX,XXX
19X9 XXX,XXX
19Y0 XXX,XXX
19Y1 XX,XXX
$X,XXX,XXX
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The Company has pledged $XXX,XXX of its investments in United States Treasury Notes as collateral under terms 
of certain of the equipment leases at December 31, 19X7.
At the expiration of the initial lease term for office and research facility space in Washington, D.C., the Company 
has the option to renew the leases for an additional three-year period on terms similar to the initial leases.
In 19X6 and 19X7, the Company entered into agreements with several medical institutions under which the institutions 
have agreed to perform certain testing and data gathering procedures in connection with the clinical trial of DSE-Z 
(an experimental drug). Compensation to the institutions includes a down payment plus additional compensation 
dependent upon various factors including, but not limited to, enrollment of patients and receipt of the required 
specimens and data for each patient. Expenses related to the agreements totaled $XXX,XXX in 19X7 and $XX,XXX 
in 19X6 and are included in research fees and clinical trials. The agreements also contain clauses for additional com­
pensation should the institutions provide specimens and data for more than the minimum number of patients 
specified in the agreements. The agreements are scheduled to expire in 19X8. As of December 3 1 ,  19X7, the total 
estimated remaining compensation to be paid, if the terms of the agreements are met, is approximately $XXX,XXX. 
The Company makes payment and recognizes expense under these agreements as the terms of the agreements are 
met to the satisfaction of the Company.
Note F—Short-Term Borrowings
The Company entered into a lending arrangement with a local bank during 19X5 whereby the bank provides the 
Company with short-term working capital loans on an "as  needed" basis. The Company pledged United States 
Treasury Notes, and accrued interest thereon, held in safekeeping by the bank, as collateral on the borrowings. 
There were no such borrowings during 19X7. The highest month-end outstanding balance during 19X6 was 
$XXX,XXX, and there were no borrowings outstanding at December 3 1 ,  19X6. Interest expense incurred on these 
borrowings totaled $X,XXX in 19X6 and is included in general and administrative expenses.
Note G—Rights to Purchase Stock
The DSE, Inc. 19X2 Incentive Stock Option Plan (the Plan) provides for grants of qualified options to officers and 
certain other key employees of the Company to purchase, in the aggregate, up to XX,XXX shares of the Company's 
Class A Common Stock. The options are exercisable after one year of employment in increments of XX% per year. 
The options expire five years and three months from the date of grant, or three months after an employee ter­
minates his employment.
During 19X4, the Company granted rights to certain employees and an independent consultant to purchase the 
Company's Class A Common Stock under substantially the same terms as those granted under the Plan.
In 19X6, the Company granted options to certain employees to purchase a total of XX,XXX shares of the Com­
pany's Class A Common Stock. These options were granted under the Plan at $X.XX per share for XX,XXX shares 
and $XX.XXX per share for X,XXX shares.
The Company has limited the number of shares that may be issued under the Plan to XX,XXX shares.
Also in 19X6, the Company granted options to members of the Company's Board of Directors and Scientific Advi­
sory Board to purchase a total of XX,XXX shares of the Company's Class A Common Stock. Of these options, 
XX,XXX were exercisable immediately and XX,XXX are exercisable ratably over a three-year period beginning with 
the date of grant. The options were granted at $XX,XXX per share. The options expire in three years and three 
months from date of grant, or three months after the individual ceases to be a member of either Board.
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The following is a summary of transactions related to all options and rights to purchase stock for the two years
ended December 3 1 ,  19X7: _
Weighted Average Price Range
Options Option Price of Options
December 3 1 ,  19X5 XX,XXX $ x.xx $ xxx-$ x  xxx
Granted XX,XXX xx.xx X,XXX- XX,XXX
Exercised (X,XXX) x.xx XXX- x,xxx
Cancelled (XX,XXX) x.xx XXX- x,xxx
Outstanding at
December 3 1 ,  19X6 XX,XXX xx.xx X,XXX- XX,XXX
Granted — — —
Exercised (X,XXX) x.xx x,xxx- x,xxx
Cancelled (XX,XXX) xx.xx XX,XXX- XX,XXX
Outstanding at
December 31, 19X7 XX,XXX $xx.xx $ x,xxx-$xx,xxx
Exercisable at
December 3 1 ,  19X7 XX,XXX
Note H—Stock Warrants
In connection with the Company's initial public offering (in 19X4), the Company sold warrants to purchase 
XXX,XXX shares of the Company's Class A Common Stock to the underwriters for $XXX. The warrants became 
exercisable on January 1 7 , 19X5. The warrants were exercisable in whole or in part at $X.XX per share and would 
expire on January 1 7 ,  19X9. On April 2 4 ,  19X6, the Company filed a Form S-1 with the Securities and Exchange 
Commission to register the XXX,XXX shares of the Company's Class A Common Stock and the registration state­
ment was declared effective October 2 8 ,  19X6. Exercise of the warrants commenced on February 2 7 ,  19X7. As of 
April 2 3 , 19X7, all XXX,XXX warrants had been exercised. Certain legal and other costs in the amount of $XX,XXX 
were offset against the total proceeds received.
Note I—Common Stock
Class A and Class B Common Stock are identical in all respects except that Class A Common Stock is freely trans­
ferable and Class B Common Stock is not.
On December 18, 19X5, the Board of Directors authorized a two-for-one stock split to be effective February 14, 
19X6. The Board also authorized an increase in the authorized shares of Common Stock to XX,XXX,XXX shares of 
Class A Common Stock and to X,XXX,XXX shares of Class B Common Stock and a change in the par value of both 
classes of Common Stock from $.XX to $.XX per share. The shareholders approved these actions on February 14, 
19X6. All loss per share amounts, stock options, rights to purchase stock and stock warrants have been adjusted 
to give effect to the stock split.
The Company issued all outstanding shares of its Class B Common Stock to Omega, Inc., a Delaware Corporation 
controlled by the Company's President and his wife, who is Secretary and Vice President for Medical Affairs of the 
Company. In return, Omega granted the Company a sole and exclusive license to all rights in the discovery of and 
in all patent applications and patents pertaining to the immunomodulators developed by the Company's Presi­
dent. All Class B shares can be converted to Class A Shares at Omega's option. Upon conversion of a total of 
XXX,XXX Class B shares, the remaining Class B shares must be converted to Class A shares. As of December 31, 
19X7, Omega has converted XXX,XXX shares of the Company's Class B Common Stock into XXX,XXX previously 
unissued shares of the Company's Class A Common Stock. All outstanding Class B shares will automatically be 
converted to Class A shares on January 1 ,  19Y6, as approved by the majority of the Company's shareholders at its 
annual meeting on May 2 8 ,  19X7.
Note J—Loss per Common Share
Loss per common share, including common share equivalents, is computed by dividing the net loss for the period 
by the weighted average number of common shares and common share equivalents outstanding during the 
period. Common share equivalents are shares issuable on the exercise of stock options, rights to purchase stock 
and stock warrants (when dilutive), net of shares assumed to be purchased with the proceeds.
The weighted average number of common shares used in the loss per share computations is XX,XXX,XXX shares 
for the year ended December 31, 19X7; XX,XXX,XXX shares for the year ended December 31, 19X6; and 
X,XXX,XXX shares for the period From inception through December 31, 19X7.
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APPENDIX
[Editor's note—The following auditor's report and financial statement disclosure is unrelated to the illustrative 
financial statements already presented. They are provided to illustrate an uncertainty involving a going concern 
which may often be encountered by development stage enterprises.]
ILLUSTRATIVE INDEPENDENT AUDITOR’S REPORT 
(Going Concern)
Independent Auditor’s Report
We have audited the accompanying balance sheets of DSE, Inc. (a development stage enterprise) as of December 
3 1 ,  19X7 and 19X6, and the related statements of operations, shareholders' equity (deficiency) and cash flows for 
the years then ended and for the period from July 1 ,  19X1 (inception) to December 3 1 , 19X7. These financial state­
ments are the responsibility of the Company's management. Our responsibility is to express an opinion on these 
financial statements based on our audit.
We conducted our audit in accordance with generally accepted auditing standards. Those standards require that 
we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of 
material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and dis­
closures in the financial statements. An audit also includes assessing the accounting principles used and signifi­
cant estimates made by management, as well as evaluating the overall financial statement presentation. We believe 
that our audit provides a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial posi­
tion of DSE, Inc. (a development stage enterprise) as of December 3 1 ,  19X7 and 19X6, and the results of its opera­
tions and its cash flows for the years then ended and for the period from July 1 ,  19X1 (inception) to December 31, 
19X7 in conformity with generally accepted accounting principles.
The accompanying financial statements have been prepared assuming that the Company will continue as a going 
concern. As discussed in Note X to the financial statements, the Company has suffered recurring losses from oper­
ations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. 
Management's plans in regard to these matters are also described in Note X. The financial statements do not 
include any adjustments that might result from the outcome of this uncertainty.
[Signature]
[Date]
• • •
Note X—Uncertainty—Going Concern
The Company's continued existence is dependent upon its ability to resolve its liquidity problems, principally by 
obtaining additional debt financing and equity capital. While pursuing additional debt and equity funding, the 
Company must continue to operate on limited cash flow generated internally. The Company has experienced a net 
loss from continuing operations for the quarter ended June 3 0 ,  19X7 of $XXX,XXX (unaudited) compared to a net 
loss from continuing operations for the quarter ended June 3 0 ,  19X6 of $X,XXX,XXX (unaudited).
The Company will have to minimize its requirements for working capital by trimming receivable levels and by con­
tinuing its cost reduction efforts. Working capital limitations continue to impinge on day-to-day operations, thus 
contributing to continued operating losses. The continued support and forebearance of its lenders will be required.
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